Scholar Rock Holding (SRRK) EV/EBITDA: History & Chart

Scholar Rock Holding Corporation(SRRK)

Biotechnology · Cambridge, MA

$56.80-1.00 (-1.73%)

At close: Aug 31, 2026, 4:00 PM ET

About Scholar Rock Holding Corporation

Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.

Cambridge, MA

289 employees

scholarrock.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: David L. Hallal

View full financials

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Scholar Rock Holding Corporation (SRRK)	$6.81B	N/A	N/A	N/A	N/A
Chemed Corporation (CHE)vs ›	$6.78B	17.45x	15.54x	18.90x	18.88x
Hims & Hers Health, Inc. (HIMS)vs ›	$6.60B	81.70x	64.87x	314.75x	314.75x
Oscar Health, Inc. (OSCR)vs ›	$7.77B	9.73x	92.80x	52.16x	52.16x
Merit Medical Systems, Inc. (MMSI)vs ›	$5.41B	17.23x	16.19x	20.07x	22.01x
Doximity, Inc. (DOCS)vs ›	$5.00B	22.88x	29.41x	37.40x	55.61x
The Ensign Group, Inc. (ENSG)vs ›	$10.04B	21.02x	24.54x	24.01x	21.64x
Henry Schein, Inc. (HSIC)vs ›	$10.23B	12.81x	11.65x	11.91x	11.67x
Insulet Corp. (PODD)vs ›	$10.30B	17.27x	31.53x	47.38x	88.32x
Universal Health Services, Inc. (UHS)vs ›	$10.31B	5.68x	6.72x	8.08x	8.15x

NAME

MARKET CAP

EV/EBITDA RATIO

TTM

Scholar Rock Holding Corporation (SRRK)

$6.81B

N/A

Chemed Corporation (CHE)vs ›

$6.78B

17.45x

15.54x

18.90x

18.88x

Hims & Hers Health, Inc. (HIMS)vs ›

$6.60B

81.70x

64.87x

314.75x

Oscar Health, Inc. (OSCR)vs ›

$7.77B

9.73x

92.80x

52.16x

Merit Medical Systems, Inc. (MMSI)vs ›

$5.41B

17.23x

16.19x

20.07x

22.01x

Doximity, Inc. (DOCS)vs ›

$5.00B

22.88x

29.41x

37.40x

55.61x

The Ensign Group, Inc. (ENSG)vs ›

$10.04B

21.02x

24.54x

24.01x

21.64x

Henry Schein, Inc. (HSIC)vs ›

$10.23B

12.81x

11.65x

11.91x

11.67x

Insulet Corp. (PODD)vs ›

$10.30B

17.27x

31.53x

47.38x

88.32x

Universal Health Services, Inc. (UHS)vs ›

$10.31B

5.68x

6.72x

8.08x

8.15x

EV/EBITDA Ratio: N/A

SRRK EV/EBITDA Ratio Metrics

SRRK Competitors' EV/EBITDA Ratio

EV/EBITDA Ratio Formula & Definition

Related Metrics